The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas

Abstract

The current study demonstrated that alisertib combined with docetaxel can mediate a better therapeutic outcome in UGC cell lines.